Rechallenge with Additional Doses of 177Lu-DOTATOC after Failure of Maintenance Therapy with Cold Somatostatin Analogs

Alexander Weich, Rudolf A. Werner, Sebastian E. Serfling, Lilja B. Solnes, Martin G. Pomper, Andreas K. Buck, Takahiro Higuchi, Steven P. Rowe

Research output: Contribution to journalArticlepeer-review

Abstract

Here, we report a case of a 52-year-old woman with a well-differentiated, metastasized neuroendocrine tumor (NET G1) of the duodenum. Initial imaging with 68Ga-DOTATOC revealed multiple sites of disease with intense uptake. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC induced partial remission. Treatment was then switched to cold somatostatin analog as a maintenance therapy. After 2 years of follow-up, progressive disease with multiple lesions in the skeleton was noted. Given the initial response to PRRT, a rechallenge with another 2 cycles of PRRT were given, and the patient had an excellent response to treatment, in particular in the skeleton.

Original languageEnglish
Pages (from-to)719-720
Number of pages2
JournalClinical Nuclear Medicine
Volume47
Issue number8
DOIs
Publication statusPublished - Aug 1 2022

Keywords

  • NEN
  • NET
  • neuroendocrine tumor
  • peptide receptor radionuclide therapy
  • PRRT
  • rechallenge

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Rechallenge with Additional Doses of 177Lu-DOTATOC after Failure of Maintenance Therapy with Cold Somatostatin Analogs'. Together they form a unique fingerprint.

Cite this